Novel Applications of Combination Therapies for Enhanced Productivity and Sustainability

Publication ID: 24-11857541_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Novel Applications of Combination Therapies for Enhanced Productivity and Sustainability,” Published Technical Disclosure No. 24-11857541_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857541_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,541.

Summary of the Inventive Concept

The inventive concept leverages the core technology of combination therapies to revolutionize various industries, including agriculture, food processing, renewable energy, water purification, and infrastructure development, by enhancing productivity, reducing waste, and promoting sustainability.

Background and Problem Solved

The original patent disclosed combination therapies for treating progeroid diseases and conditions, cellular aging, and cardiovascular and bone diseases. However, these therapies have untapped potential for application in other fields. The inventive concept addresses the limitations of the original patent by exploring new use cases, thereby unlocking the full potential of these combination therapies.

Detailed Description of the Inventive Concept

The inventive concept involves the administration of a therapeutically effective amount of a farnesyltransferase inhibitor and an mTOR inhibitor to various systems, including agricultural crops, perishable food products, renewable energy sources, water purification systems, and infrastructure materials. This results in enhanced yields, reduced spoilage, optimized energy production, reduced biofouling, and improved material durability, respectively.

Novelty and Inventive Step

The inventive concept's novelty lies in its unexpected application of combination therapies to entirely new fields, solving problems that were not previously considered. The inventive step is the recognition of the potential for these therapies to have a profound impact on productivity and sustainability across multiple industries.

Alternative Embodiments and Variations

Alternative embodiments may include varying the dosages, formulations, or administration methods of the combination therapies, as well as exploring different types of inhibitors or additional active ingredients. Variations may also involve adapting the inventive concept to address specific challenges or requirements within each target industry.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential across multiple industries, including agriculture, food processing, renewable energy, water purification, and infrastructure development. The market for these applications is vast, with potential customers including farmers, food manufacturers, energy producers, municipalities, and construction companies.

Field of Art

Pharmaceutical and biotechnology research, with expertise in molecular inhibitor therapies, cellular aging mechanisms, and therapeutic combination strategies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or pharmacology, familiar with inhibitor mechanisms, combination therapy principles, and cross-disciplinary applications of targeted molecular interventions

Obviousness Rationale

A PHOSITA would recognize that the fundamental mechanism of farnesyltransferase and mTOR inhibitors can be systematically applied beyond medical treatments to address cellular stress and optimization challenges across multiple domains. The source patent establishes the core therapeutic combination, which a skilled practitioner would naturally explore for broader applications given the inhibitors' fundamental cellular interaction properties. The PTD's variations represent predictable extensions of the original combination therapy concept by applying known molecular intervention strategies to different systemic challenges.

Obvious Combinations & Variations

Source Patent Element
Combination of farnesyltransferase and mTOR inhibitors for treating atherosclerosis
PTD Variation
Applying the same inhibitor combination to enhance agricultural crop yields
Obviousness Reasoning
Known cellular stress reduction techniques can be predictably applied to improve biological system performance across different domains
Source Patent Element
Specific dosage ranges for inhibitor administration in medical treatments
PTD Variation
Adapting dosage protocols for food preservation and infrastructure material enhancement
Obviousness Reasoning
Dosage optimization is a standard engineering practice that a PHOSITA would recognize as transferable between different application contexts
Source Patent Element
Simultaneous administration of multiple molecular inhibitors
PTD Variation
Concurrent application of inhibitors in renewable energy and water purification systems
Obviousness Reasoning
Parallel intervention strategies represent a predictable extension of combination therapy principles to solve systemic performance challenges
Source Patent Element
Targeting cellular aging and metabolic processes
PTD Variation
Using inhibitors to reduce spoilage and enhance material durability
Obviousness Reasoning
Molecular mechanisms controlling cellular degradation are fundamentally similar across biological and material systems
35 U.S.C. § 103 Summary: Based on US Patent 11857541's disclosure of combination therapies involving farnesyltransferase and mTOR inhibitors, the present publication demonstrates that a person having ordinary skill in the art would find the proposed variations obvious and predictable extensions of the original therapeutic approach, thereby rendering potential claims in this domain anticipated and non-patentable under standard obviousness analysis.

Original Patent Information

Patent NumberUS 11,857,541
TitleCombination therapies for treatment of laminopathies, cellular aging, and atherosclerosis